About Durata Therapeutics
Durata Therapeutics is a company based in Chicago (United States) founded in 2009 was acquired by Actavis in October 2014. Durata Therapeutics has completed 1 acquisition, including Vicuron Pharmaceuticals. Durata Therapeutics operates in a competitive market with competitors including Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
- Headquarter Chicago, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Durata Therapeutics
Investors in Durata Therapeutics
Durata Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Actavis and PDL BioPharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biopharmaceutical company undergoing dissolution and asset distribution processes.
|
Locked | Locked | Locked | |
|
Manufacturer of generic products
|
Locked | Locked | Locked |
Investor details for Durata Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Durata Therapeutics
Durata Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Vicuron Pharmaceuticals.
Investment portfolio details for Durata Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Anti-infectives for hospital-based and community-acquired infections
|
Locked | Locked | 1995 | Locked |
Complete acquisition details for Durata Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Durata Therapeutics
Detailed financials for Durata Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Durata Therapeutics Comparisons
Peer comparison for Durata Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Durata Therapeutics
Durata Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Eligo Bioscience, Lodo Therapeutics and Symbiomix Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
|
| Locked | Locked | Locked |
Late-stage biopharma antibiotics for gynecological infections are developed.
|
|
| Locked | Locked | Locked |
Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology
|
Detailed competitors of Durata Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Durata Therapeutics
Complete news archive for Durata Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Durata Therapeutics
Durata Therapeutics was founded in 2009 and raised its 1st funding round 4 years after it was founded.
Durata Therapeutics is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Durata Therapeutics was established in 2009 in Chicago, United States, as a clinical-stage pharmaceutical company. Focus is placed on addressing infectious diseases through the advancement of treatments. Operations center on the late-stage development of dalbavancin, an intravenous antibiotic intended for acute bacterial skin and skin structure infections in hospital and outpatient environments. The domain duratatherapeutics.com is utilized for online presence.
Durata Therapeutics's top competitors include Insmed, MaaT Pharma and Basilea.
Durata Therapeutics has made 1 acquisition, including Vicuron Pharmaceuticals.
Durata Therapeutics has 2 investors. Key investors include Actavis, and PDL BioPharma.